1. Home
  2. REGN vs PCAR Comparison

REGN vs PCAR Comparison

Compare REGN & PCAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REGN
  • PCAR
  • Stock Information
  • Founded
  • REGN 1988
  • PCAR 1905
  • Country
  • REGN United States
  • PCAR United States
  • Employees
  • REGN N/A
  • PCAR N/A
  • Industry
  • REGN Biotechnology: Pharmaceutical Preparations
  • PCAR Auto Manufacturing
  • Sector
  • REGN Health Care
  • PCAR Consumer Discretionary
  • Exchange
  • REGN Nasdaq
  • PCAR Nasdaq
  • Market Cap
  • REGN 59.5B
  • PCAR 53.8B
  • IPO Year
  • REGN 1991
  • PCAR N/A
  • Fundamental
  • Price
  • REGN $585.48
  • PCAR $98.52
  • Analyst Decision
  • REGN Buy
  • PCAR Hold
  • Analyst Count
  • REGN 23
  • PCAR 9
  • Target Price
  • REGN $794.83
  • PCAR $104.78
  • AVG Volume (30 Days)
  • REGN 1.1M
  • PCAR 3.1M
  • Earning Date
  • REGN 10-28-2025
  • PCAR 10-21-2025
  • Dividend Yield
  • REGN 0.60%
  • PCAR 4.38%
  • EPS Growth
  • REGN 5.03
  • PCAR N/A
  • EPS
  • REGN 39.67
  • PCAR 5.83
  • Revenue
  • REGN $14,214,200,000.00
  • PCAR $31,099,600,000.00
  • Revenue This Year
  • REGN N/A
  • PCAR N/A
  • Revenue Next Year
  • REGN $4.74
  • PCAR $7.82
  • P/E Ratio
  • REGN $14.76
  • PCAR $16.90
  • Revenue Growth
  • REGN 5.38
  • PCAR N/A
  • 52 Week Low
  • REGN $476.49
  • PCAR $84.65
  • 52 Week High
  • REGN $1,024.36
  • PCAR $118.81
  • Technical
  • Relative Strength Index (RSI)
  • REGN 53.18
  • PCAR 48.86
  • Support Level
  • REGN $555.00
  • PCAR $96.87
  • Resistance Level
  • REGN $618.01
  • PCAR $100.24
  • Average True Range (ATR)
  • REGN 17.27
  • PCAR 2.43
  • MACD
  • REGN 1.89
  • PCAR -0.12
  • Stochastic Oscillator
  • REGN 52.72
  • PCAR 37.44

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

About PCAR PACCAR Inc.

Paccar is a leading manufacturer of medium- and heavy-duty trucks under the premium nameplates Kenworth and Peterbilt, which are primarily sold in the Americas and Australia, and DAF, which primarily services Europe and South America. The trucks segment (74% sales) goes to market through a network of 2,200 independent dealers. Paccar maintains an internal finance subsidiary that provides retail and wholesale financing for customers and dealers (6% sales). In recent years, Paccar has aggressively grown its parts business (20% sales), which include engines, axles, and transmissions for its own truck brands as well as independent producers. The company commands approximately 30% of the Class 8 market share in North America and 15% of the heavy-duty market share in Europe.

Share on Social Networks: